Network |
Study Title |
NCT # |
IND Y/N |
Health Authority |
# of sites |
# of participants |
Status |
ADRN |
Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis (LEADS - ADRN12) |
pending |
N |
FDA IND exempt |
9 |
600 |
In startup; to be initiated in Q3 2022; expected duration 3 years |
ADRN |
A Pilot Study to Evaluate the Survival of Transplanted Staphylococcus hominis A9 on the Skin of Adults with Moderate-to-Severe Atopic Dermatitis |
NCT05177328 |
Y |
FDA |
1 |
20 |
In startup; to be initiated in Q2 2022; expected duration 1 year |
CoFAR |
Systems Biology in Early Atopy birth cohort (SUNBEAM - CoFAR12) |
NCT04798079 |
N |
FDA IND Exempt |
12 |
2500 |
Ongoing; recruitment to be completed by Q1 2024; study to be completed by Q4 2027 |
CoFAR |
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children (OUTMATCH - CoFAR11) |
NCT03881696 |
Y |
FDA |
10 |
165 |
Ongoing; enrollment to be completed by Q3 2022, study to be completed by Q4 2025 |
ICAC/CAUSE |
Cockroach Immunotherapy in Inner City Asthma (CRITICAL- ICAC28) |
NCT03541187 |
Y |
FDA |
11 |
80 |
Ongoing, fully enrolled; study to be completed by June 2022; not all analyses may be completed by AA-SCCC initiation |
ICAC/CAUSE |
Urban Environment and Childhood Asthma birth cohort (URECA - ICAC07) |
NCT00114881 |
N |
FDA IND Exempt |
4 |
440 |
Ongoing, fully enrolled; to be completed by Q4 2024 |
ICAC/CAUSE |
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent with Immune-Based Therapy: A Systems Approach Phase 2 (MUPPITS 2 - ICAC30) |
NCT03292588 |
Y |
FDA |
9 |
290 |
Study completed; some publications pending |
CAUSE |
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children, and Adolescents |
NCT05347771 |
N |
FDA IND exempt |
7 |
240 |
In startup; to be initiated in Q2 2022; expected duration 3 years |
CAUSE |
Registry of Asthma Characterization and Recruitment 3 (RACR3 – CAUSE02) |
NCT05272241 |
N |
FDA Exempt |
7 |
1500 |
Ongoing; expected duration 6 years |
CAUSE |
Mechanisms Underlying Asthma Symptoms and Exacerbations Examined Across T2 Status in Children (CHEETAH – CAUSE03 ) |
pending |
pending |
FDA expected to be IND exempt |
7 |
250 |
In startup; to be initiated in Q4 2022; expected duration 3 years |
ITN |
Anti-TSLP (MEDI9929/AMG157) plus Antigen-Specific Immunotherapy for the Induction of Tolerance in individuals with cat allergy (CATNIP - ITN057AD) |
NCT02237196 |
Y |
FDA |
9 |
120 |
Study completed; publications pending |
ITN |
Follow up of LEAP Participants and Their Families (LEAP TRIO – ITN070AD) |
NCT03546413 |
N |
MHRA Exempt |
1 |
1800 |
Ongoing; recruitment/study to be completed by Q3 2022 |
ITN |
A Randomized, Double-blind, Single-center, Placebo-controlled Study of Antigen-specific Sublingual immunotherapy plus Dupilumab for Induction of Tolerance in Adults with Seasonal Allergic Rhinitis (GRADUATE – ITN084AD) |
NCT04502966 |
CTA (UK) |
MHRA (UK) |
1 |
105 |
Ongoing, fully enrolled; study to be completed by Q2 2025 |
ITN |
Exposure to Vaginal Microbiome in C-section Infants at High-Risk for Allergies (ACTIVATE - ITN079AD) |
NCT03567707 |
Y |
FDA |
2 |
95 |
Ongoing; enrollment to be completed by Q2 2023; study to be completed by Q4 2026 |
ITN |
Efficacy of Tezepelumab in Peanut Oral Immunotherapy: A Double-Blind, Randomized, Placebo-Controlled Trial (ZENITH – ITN097AD) |
pending |
Y |
FDA |
15 |
128 |
In startup; to be initiated in Q1 2023; expected duration 4 years |